FDA approves new drug to prevent HIV infection

The Food and Drug Administration yesterday approved a new pre-exposure prophylaxis (PrEP) for certain adults and adolescents who do not have HIV but are at risk for infection from sex. The drug, Descovy, previously was approved for use with other antiretoviral drugs to treat HIV infection in adults and pediatric patients. “PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” said Jeffrey Murray, M.D., deputy director for the division of antiviral products at FDA’s Center for Drug Evaluation and Research. “This approval provides more prevention options for certain patients at-risk for acquiring HIV.”
Related News Articles
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The American Heart Association and American College of Cardiology Aug. 14 released new guidelines on high blood pressure prevention, suggesting earlier…
Headline
Josh Neff, CEO of CommonSpirit Mercy Hospital, discusses a new cutting-edge communication platform that sends patient EKGs directly from the ambulance to the…
Headline
A JAMA study published yesterday found that more adults age 45-49 have been diagnosed with colorectal cancer, a finding that coincides with recommendations by…
Headline
A study published June 25 by the Journal of the American Heart Association found that heart disease death rates fell 66% from 1970 to 2022. Deaths from heart…
Headline
The White House May 22 released its Make America Healthy Again report that focuses on childhood chronic disease. The report highlights findings from the MAHA…